{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neurotransmitter+Agents",
    "query": {
      "condition": "Neurotransmitter Agents"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 34,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neurotransmitter+Agents&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T09:45:51.334Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04922593",
      "title": "Relative Bioavailability of LY03010 Compared to Listed Drug",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia",
        "Psychotic Disorders",
        "Mood Disorders",
        "Schizophrenia Spectrum",
        "Mental Disorders",
        "Antipsychotic Agents",
        "Tranquilizing Agents",
        "Central Nervous System Depressants",
        "Physiological Effects of Drugs",
        "Psychotropic Drugs",
        "Neurotransmitter Agents",
        "Molecular Mechanisms of Pharmacological Action"
      ],
      "interventions": [
        {
          "name": "LY03010; paliperidone palmitate",
          "type": "DRUG"
        },
        {
          "name": "INVEGA SUSTENNA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Luye Pharma Group Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 281,
      "start_date": "2021-01-13",
      "completion_date": "2022-04-15",
      "has_results": false,
      "last_update_posted_date": "2023-04-25",
      "last_synced_at": "2026-05-22T09:45:51.334Z",
      "location_count": 9,
      "location_summary": "Garden Grove, California • Lemon Grove, California • Torrance, California + 6 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Lemon Grove",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04922593"
    },
    {
      "nct_id": "NCT05615948",
      "title": "Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Treatment Resistant Depression",
        "Major Depressive Disorder",
        "Analgesia",
        "Ketamine",
        "Peripheral Nervous System Agents",
        "Central Nervous System Depressants",
        "Neurotransmitter Agents",
        "Anti-Inflammatory Agents",
        "Physiological Effects of Drugs",
        "Sensory System Agents",
        "Analgesics, Non-Narcotic",
        "Anti-Inflammatory Agents, Non-Steroidal",
        "Depressive Symptoms"
      ],
      "interventions": [
        {
          "name": "VTS-K",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Theresa Jacob, PhD, MPH",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 15,
      "start_date": "2022-12-06",
      "completion_date": "2024-05-17",
      "has_results": false,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-05-22T09:45:51.334Z",
      "location_count": 1,
      "location_summary": "Brooklyn, New York",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05615948"
    },
    {
      "nct_id": "NCT03250117",
      "title": "Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "Ropinirole oral product",
          "type": "DRUG"
        },
        {
          "name": "Ropinirole Implant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Titan Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "30 Years to 80 Years"
      },
      "enrollment_count": 6,
      "start_date": "2017-10-10",
      "completion_date": "2018-05-22",
      "has_results": true,
      "last_update_posted_date": "2023-05-06",
      "last_synced_at": "2026-05-22T09:45:51.334Z",
      "location_count": 3,
      "location_summary": "Orlando, Florida • Farmington Hills, Michigan • Kirkland, Washington",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Farmington Hills",
          "state": "Michigan"
        },
        {
          "city": "Kirkland",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03250117"
    },
    {
      "nct_id": "NCT05585125",
      "title": "A Preliminary Study for INFORMED",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Heart Failure",
        "Heart Failure, Diastolic",
        "Heart Failure With Preserved Ejection Fraction",
        "Cardiac Failure",
        "Heart Diseases"
      ],
      "interventions": [
        {
          "name": "Beta blocker",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2024-02-07",
      "completion_date": "2026-07",
      "has_results": false,
      "last_update_posted_date": "2025-10-23",
      "last_synced_at": "2026-05-22T09:45:51.334Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05585125"
    },
    {
      "nct_id": "NCT01204723",
      "title": "Medications Development for the Treatment of Cannabis Related Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Nicotine Withdrawal",
        "Marijuana Dependence",
        "Cannabis Dependence",
        "Nicotine Dependence",
        "Cannabis Abuse"
      ],
      "interventions": [
        {
          "name": "Placebo Aprepitant",
          "type": "DRUG"
        },
        {
          "name": "Active Aprepitant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 63,
      "start_date": "2009-08",
      "completion_date": "2012-04",
      "has_results": false,
      "last_update_posted_date": "2012-06-01",
      "last_synced_at": "2026-05-22T09:45:51.334Z",
      "location_count": 2,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01204723"
    },
    {
      "nct_id": "NCT06511908",
      "title": "Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Suicide",
        "Depressive Disorder, Treatment-Resistant",
        "Ketamine",
        "Molecular Mechanisms of Pharmacological Action",
        "Neurotransmitter Agents",
        "Excitatory Amino Acid Agents",
        "Physiological Effects of Drugs",
        "Depressive Disorder, Major",
        "Depressive Disorder",
        "Depression",
        "Mental Disorders",
        "Mood Disorders",
        "Behavioral Symptoms"
      ],
      "interventions": [
        {
          "name": "(2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Mental Health (NIMH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 50,
      "start_date": "2024-11-06",
      "completion_date": "2027-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-05-22T09:45:51.334Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06511908"
    },
    {
      "nct_id": "NCT04412096",
      "title": "Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma",
        "OHT - Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Timolol 0.5% ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost 0.005% Ophthalmic Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ohio State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 59,
      "start_date": "2020-11-23",
      "completion_date": "2025-05-22",
      "has_results": false,
      "last_update_posted_date": "2026-03-04",
      "last_synced_at": "2026-05-22T09:45:51.334Z",
      "location_count": 3,
      "location_summary": "Rochester, Minnesota • Omaha, Nebraska • Columbus, Ohio",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04412096"
    },
    {
      "nct_id": "NCT05143424",
      "title": "Evaluation of the Interactions of Cannabidiol (CBD) With Morphine",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Opioid Use Disorder"
      ],
      "interventions": [
        {
          "name": "Morphine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute on Drug Abuse (NIDA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 60,
      "start_date": "2021-11-04",
      "completion_date": "2024-12-01",
      "has_results": false,
      "last_update_posted_date": "2024-03-27",
      "last_synced_at": "2026-05-22T09:45:51.334Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05143424"
    },
    {
      "nct_id": "NCT06752759",
      "title": "Nebulized Ketamine for the Treatment of Major Depressive Disorder",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Severe Depression",
        "Moderate Depression",
        "Ketamine",
        "Midazolam",
        "Peripheral Nervous System Agents",
        "Central Nervous System Agents",
        "Neurotransmitter Agents",
        "Physiologic Effects of Drugs",
        "Sensory System Agents",
        "Analgesics, Non-Narcotic",
        "Anti-Inflammatory Agents, Non-Steroidal",
        "Depressive Symptom",
        "Hypnotics and Sedatives",
        "Anti-anxiety Agents",
        "Tranquilizing Agents",
        "Psychotropic Drugs",
        "Anesthetics Agent"
      ],
      "interventions": [
        {
          "name": "nebulized ketamine",
          "type": "DRUG"
        },
        {
          "name": "nebulized midazolam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Theresa Jacob, PhD, MPH",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "88 Years",
        "sex": "ALL",
        "summary": "18 Years to 88 Years"
      },
      "enrollment_count": 40,
      "start_date": "2024-10-16",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-05-22T09:45:51.334Z",
      "location_count": 1,
      "location_summary": "Brooklyn, New York",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06752759"
    },
    {
      "nct_id": "NCT01366196",
      "title": "Pregabalin for the Treatment of Pain After Posterior Spinal Fusions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Lumbar Spinal Fusions"
      ],
      "interventions": [
        {
          "name": "Pregabalin 150 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hospital for Special Surgery, New York",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "21 Years to 80 Years"
      },
      "enrollment_count": 86,
      "start_date": "2008-10",
      "completion_date": "2012-02",
      "has_results": true,
      "last_update_posted_date": "2022-04-14",
      "last_synced_at": "2026-05-22T09:45:51.334Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01366196"
    }
  ]
}